外用免疫治疗对角化不良型斑秃日本患者的影响。

Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.

机构信息

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

出版信息

Allergol Int. 2020 Apr;69(2):274-278. doi: 10.1016/j.alit.2019.10.008. Epub 2019 Nov 22.

DOI:10.1016/j.alit.2019.10.008

PMID:31767273

Abstract

BACKGROUND

The Japanese guidelines for the treatment of alopecia areata list topical immunotherapies as a drug therapy for this condition. However, there is insufficient evidence of its efficacy to support this recommendation. Thus, we sought to clarify the effect of topical immunotherapy on the progression and severity of alopecia areata in Japanese patients.

METHODS

To evaluate the effect of topical immunotherapy with squaric acid dibutylester (SADBE) in alopecia areata patients, we performed a retrospective cohort study on 49 alopecia patients who had received topical immunotherapy with SADBE. Patients were evaluated by the change in alopecia severity at 6 and 12 months after the initiation of topical immunotherapy. The improvement rate was calculated by determination of the complete and partial responses rate to treatment with topical immunotherapy by application of SADBE.

RESULTS

The improvement rate in all alopecia patients treated with SADBE topical immunotherapy was 57.8% (complete response; 11.1% and partial response; 46.7%).

CONCLUSIONS

Topical immunotherapy with SADBE is an effective treatment for alopecia areata. Therefore, the current treatment recommendations for alopecia areata with topical immunotherapies are appropriate.

摘要

背景

日本斑秃治疗指南将局部免疫疗法列为该疾病的药物治疗方法。然而，其疗效的证据不足，无法支持这一推荐。因此，我们试图阐明局部免疫疗法对日本斑秃患者疾病进展和严重程度的影响。

方法

为了评估 Squaric acid dibutylester（SADBE）局部免疫疗法治疗斑秃的效果，我们对 49 名接受 SADBE 局部免疫疗法的斑秃患者进行了回顾性队列研究。通过在开始局部免疫疗法后 6 个月和 12 个月时评估脱发严重程度的变化来评估患者。通过应用 SADBE 确定治疗的完全和部分反应率来计算改善率。